A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD (HCY)
Overview
The purpose of this study is to assess homocysteine metabolism and systemic endothelial function at the early stages of the disease and determine the prognostic value of homocysteine, related metabolites, and markers of endothelial function and injury to estimate renal disease severity and progression in patients with early Autosomal Dominant Polycystic Kidney Disease (ADPKD).
The investigators’ broad objective is to assess homocysteine metabolism and systemic endothelial function at the early stages of the disease and determine the prognostic value of homocysteine, related metabolites, and markers of endothelial function and injury to estimate renal disease severity and progression in patients with early ADPKD.
Participants in this study will have a blood and a urine sample collected to determine biomarkers of oxidative stress, endothelial function and injury, homocysteine, and related metabolite levels. In addition, peripheral arterial tonometry (PAT) will determine systemic endothelial function, and an abdominal MRI will be performed to determine the patient’s total kidney volume (TKV).
Eligibility Criteria
- Male and Female subjects, 18-40 years of age, inclusive
- Previous diagnosis of ADPKD
- Estimated GFR>70 mL/min/1.73m^2
- Does not have Diabetes mellitus
- Is not a pregnant female
Additional exclusion/inclusion criteria may apply
Locations
Minnesota
- Mayo Clinic
- Rochester, MN 55905
- Contact: Keith S Weincouff, ACRC 507-266-2108 weincouff.keith@mayo.edu
- Contact: Maria V Irazabal, M.D.;Ph.D. 507-293-6388 irazabalmira.maria@mayo.edu
Principal Investigator: Maria V Irazabal, M.D.; Ph.D.